

Clinical Trial Protocol

Iranian Registry of Clinical Trials

10 Jun 2026

Safety and efficacy of "GernaHair Premium" supplement on Telogen Effluvium hair loss: A triple-blind, randomized, placebo-controlled clinical trial

Protocol summary

Study aim

Evaluating the effectiveness and safety of oral capsules "Gernahair" in preventing hair loss, increasing hair growth and strength, and improving nail parameters in telogen effluvium patients

Design

A randomized, triple-blind, placebo-controlled clinical trial with a parallel group conducted on 57 patients

Settings and conduct

The study is conducted on telogen effluvium patients in Razi Hospital. The patients are randomly divided into 3 parallel groups. The patient, the dermatologist and the data analyst are unaware of the treatment type. All three groups of patients use supplements with the same packaging. Hair loss reduction, hair growth and strength, and nail quality are assessed during 3 visits in 0-3-6 months.

Participants/Inclusion and exclusion criteria

Inclusion Criteria: Patients with female pattern hair loss Ludwig type II or I, Diffuse hair loss, Changes in hair structure, and nail growth disorders Exclusion Criteria: Symptomatic diffuse alopecia, FPHL Ludwig type III, androgenic alopecia, alopecia areata

Intervention groups

The first group receives 3 capsules of Gernahair Premium daily, the second group receives 1 capsule, and the third group receives 3 placebo capsules for 6 months. This supplement contains 30 mg thiamine, 60 mg calcium pantothenate, 100 mg medicinal yeast, 20 mg L-cystine, 20 mg keratin, and 20 mg PABA per 1 capsule and the placebo contains microcrystalline cellulose.

Main outcome variables

Anagen hair rate, hair count, density, and cumulative hair shaft diameter, in the beginning, and after 3 and 6 months of treatment The patient's overall satisfaction with the treatment rating from 0 to 100

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20240218061044N1**

Registration date: **2024-04-29, 1403/02/10**

Registration timing: **registered_while_recruiting**

Last update: **2024-04-29, 1403/02/10**

Update count: **0**

Registration date

2024-04-29, 1403/02/10

Registrant information

Name

Maryam Nasimi

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 21 5561 8989

Email address

m-nasimi@sina.tums.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2024-04-20, 1403/02/01

Expected recruitment end date

2024-07-22, 1403/05/01

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Safety and efficacy of "GernaHair Premium" supplement on Telogen Effluvium hair loss: A triple-blind, randomized, placebo-controlled clinical trial

Public title

Efficacy and safety of GernaHair Premium on hair loss

Purpose

Treatment

Inclusion/Exclusion criteria**Inclusion criteria:**

Patients with a history of hair loss who had clinical findings of female pattern hair loss (FPHL) Ludwig type II or I and parietal center telogen hair rate of more than 20%, as determined by TrichoScan Patients with diffuse hair loss without any evidence of underlying disease in medical history Patients with acquired or age-related damage to the hair structure, including thinning, brittle, or split end hair Patients with nail growth disorders such as soft or brittle nails with no evidence of underlying disease in the medical history

Exclusion criteria:

Symptomatic diffuse alopecia (eg, due to iron deficiency or thyroid disorder) FPHL Ludwig type III Androgenic alopecia with or without virile symptoms as a result of polycystic ovaries, late-onset adrenogenital syndrome and ovarian, adrenal, or pituitary tumors Systemic autoimmune diseases Debilitating diseases (eg, AIDS or malignancy) Alopecia Areata Inflammatory ulcer or other ulcerative alopecia Other inflammatory conditions affecting the scalp (such as seborrheic dermatitis, psoriasis, or contact dermatitis) Receiving any treatment for hair loss or participating in another clinical trial for 3 months before entering the study Receiving medications that may cause hair loss (such as anticoagulants, lipid-lowering drugs, retinoids, antiepileptic drugs, antithyroid drugs, androgens, progesterones with androgenic or relative toxic effects, Angiotensin Converting Enzyme inhibitors(ACE)) within 3 months before entering the study. Receiving drugs containing sulfonamides (interference with PABA) Initiation or termination of hormone replacement therapy or hormonal contraception within 6 months before entering the study Any type of hormone replacement therapy or oral contraceptive containing progesterone with an androgenic effect (such as Norethisterone, Norgestrel, levonorgestrel, Linsternol or Tibolone) Pregnancy or breastfeeding Known sensitivity to any of components

Age

From **12 years** old

Gender

Both

Phase

N/A

Groups that have been masked

- Participant
- Care provider
- Data analyser

Sample size

Target sample size: **57**

Randomization (investigator's opinion)

Randomized

Randomization description

Using the block randomization method, patients are divided into three groups A, B, and C, where group A receives 3 Geranahir daily, group B receives 1 Geranahir daily, and group C receives placebo. A random numbers table is used to prepare a random list. If the generated number is between 0 and 2, the patient receives group A treatment, if it is between 3 and 5, the patient receives group B treatment, and if it is between 6 and 8, the patient receives placebo. According to the output of the Random Allocation Software, each patient has a special code that Determines which medicine they receive.

Blinding (investigator's opinion)

Triple blinded

Blinding description

Gernahair premium boxes, one group of which contains the active substance and the other one contains the placebo, are prepared in a completely similar way to each other, and are randomly delivered to patients. The patient, the dermatologist, and the data analyzer are unaware of the type of treatment they are receiving also, the participants are unaware of the presence of other study groups and do not know that the number of GernaHair received in one day is different for every group.

Placebo

Used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Ethics committee of Tehran University of Medical Sciences

Street address

Central Administration Building, University of Tehran, Qods Ave., Keshavarz Blvd

City

Tehran

Province

Tehran

Postal code

1417653761

Approval date

2024-02-04, 1402/11/15

Ethics committee reference number

IR.TUMS.MEDICINE.REC.1402.625

Health conditions studied

1

Description of health condition studied

Telogen Effluvium

ICD-10 code

L65.0

ICD-10 code description

Telogen effluvium

Primary outcomes

1

Description

Anagen hair rate

Timepoint

Before treatment, after 3 and 6 months of treatment

Method of measurement

Measuring the anagen hair rate in an area equal to 1.8 square centimeters in the center of the parietal of the scalp, while imaging the specific area and using the Trichoscan software

2

Description

Hair count

Timepoint

Before treatment, after 3 and 6 months of treatment

Method of measurement

Measuring the hair count in an area equal to 1.8 square centimeters in the center of the parietal of the scalp, while imaging the specific area and using the Trichoscan software

3

Description

Hair density

Timepoint

Before treatment, after 3 and 6 months of treatment

Method of measurement

Measuring the hair density in an area equal to 1.8 square centimeters in the center of the parietal of the scalp, while imaging the specific area and using the Trichoscan software

4

Description

Cumulative hair shaft diameter

Timepoint

Before treatment, after 3 and 6 months of treatment

Method of measurement

Measuring the cumulative hair shaft diameter in an area equal to 1.8 square centimeters in the center of the parietal of the scalp, while imaging the specific area and using the Trichoscan software

Secondary outcomes

1

Description

Participant's satisfaction with treatment

Timepoint

Before treatment, after 3 and 6 months of treatment

Method of measurement

The patient's overall satisfaction with the treatment will be evaluated from 0 to 100 so that 0 is a sign of absolute dissatisfaction and 100 is a sign of maximum consumer satisfaction.

Intervention groups

1

Description

Intervention group number 1: This group will take 3 Gernahair Premium capsules orally for 6 months. This supplement contains 90 mg thiamine, 180 mg calcium pantothenate, 300 mg medicinal yeast, 60 mg L-cystine, 60 mg keratin, and 60 mg PABA per 3 capsules.

Category

Treatment - Other

2

Description

Intervention group number 2 : This group will take 1 Gernahair Premium capsules orally for 6 months. This supplement contains 30 mg thiamine, 60 mg calcium pantothenate, 100 mg medicinal yeast, 20 mg L-cystine, 20 mg keratin, and 20 mg PABA per 1 capsules.

Category

Treatment - Other

3

Description

Control group: This group will receive 3 placebo capsules daily for 6 months that contain microcrystalline cellulose.

Category

Placebo

Recruitment centers

1

Recruitment center

Name of recruitment center

Razi hospital

Full name of responsible person

Maryam nasimi

Street address

Razi Hospital , Vahdate-e-eslami St , Tehran , Iran

City

Tehran

Province

Tehran

Postal code

1199663911

Phone

+98 21 5288 8282

Fax

+98 21 5563 4461

Email

razihospital@sina.tums.ac.ir

Web page address

https://razihospital.tums.ac.ir

Sponsors / Funding sources

1

Sponsor**Name of organization / entity**

Tehran University of Medical Sciences

Full name of responsible person

Maryam nasimi

Street address

University of Tehran, Qods Ave., Keshavarz Blvd

City

Tehran

Province

Tehran

Postal code

1417653761

Phone

+98 21 8163 3102

Fax

+98 21 6649 9713

Email

tumspr@tums.ac.ir

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

No

Title of funding source

Tose-e Teb Adrian Salamat co.

Proportion provided by this source

100

Public or private sector

Private

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin**Type of organization providing the funding**

Industry

Person responsible for general inquiries

Contact**Name of organization / entity**

Tehran University of Medical Sciences

Full name of responsible person

Maryam Nasimi

Position

Associate professor

Latest degree

Specialist

Other areas of specialty/work

Dermatology

Street address

Razi Hospital , Vahdate-e-eslami St , Tehran , Iran

City

Tehran

Province

Tehran

Postal code

1199663911

Phone

+98 21 5561 8989

Fax**Email**

m-nasimi@sina.tums.ac.ir

Person responsible for scientific inquiries

Contact**Name of organization / entity**

Tehran University of Medical Sciences

Full name of responsible person

Maryam Nasimi

Position

Associate professor

Latest degree

Specialist

Other areas of specialty/work

Dermatology

Street address

Razi Hospital , Vahdate-e-eslami St , Tehran , Iran

City

Tehran

Province

Tehran

Postal code

1199663911

Phone

+98 21 5561 8989

Fax**Email**

m-nasimi@sina.tums.ac.ir

Person responsible for updating data

Contact**Name of organization / entity**

Tehran University of Medical Sciences

Full name of responsible person

Maryam Nasimi

Position

Associate professor

Latest degree

Specialist

Other areas of specialty/work

Dermatology

Street address

Razi Hospital , Vahdate-e-eslami St , Tehran , Iran

City

Tehran

Province

Tehran

Postal code

1199663911

Phone

+98 21 5561 8989

Fax

Email

m-nasimi@sina.tums.ac.ir

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Undecided - It is not yet known if there will be a plan to make this available

Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available